Publisher Correction: Targeting co-stimulatory molecules in autoimmune disease

Affiliations

¹ Institute of Immunity & Transplantation, Division of Infection & Immunity, University College London, Royal Free Campus, London, UK.
² Early Oncology Discovery, Early Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.
³ Autoimmunity, Transplantation and Inflammation Disease Area, Novartis Institutes for Biomedical Research, Basel, Switzerland.
⁴ Institute of Immunity & Transplantation, Division of Infection & Immunity, University College London, Royal Free Campus, London, UK. lucy.walker@ucl.ac.uk.

Published Erratum

Natalie M Edner et al. Nat Rev Drug Discov. 2021 Jan.

. 2021 Jan;20(1):82.

doi: 10.1038/s41573-020-00116-x.

¹ Institute of Immunity & Transplantation, Division of Infection & Immunity, University College London, Royal Free Campus, London, UK.
² Early Oncology Discovery, Early Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.
³ Autoimmunity, Transplantation and Inflammation Disease Area, Novartis Institutes for Biomedical Research, Basel, Switzerland.
⁴ Institute of Immunity & Transplantation, Division of Infection & Immunity, University College London, Royal Free Campus, London, UK. lucy.walker@ucl.ac.uk.

No abstract available

Erratum for

Targeting co-stimulatory molecules in autoimmune disease.
Edner NM, Carlesso G, Rush JS, Walker LSK. Edner NM, et al. Nat Rev Drug Discov. 2020 Dec;19(12):860-883. doi: 10.1038/s41573-020-0081-9. Epub 2020 Sep 16. Nat Rev Drug Discov. 2020. PMID: 32939077 Review.